MedTrace Logo

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

NCT01795144 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-04-10

No results posted yet for this study

Summary

The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.

Conditions

  • Monogenic Diabetes

Interventions

DRUG

GLP-1

OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

DRUG

Exendin 9-39

OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Siri Atma W Greeley, MD, PhD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01795144 on ClinicalTrials.gov